-
1
GLP-1 receptor agonists may reduce ED visits and hospitalizations for chronic migraine.
-
2
The study compared GLP-1 RAs to topiramate.
-
3
21,994 patients were analyzed.
-
4
24% of GLP-1 RA users visited the ED compared to 26% for topiramate.
-
5
GLP-1 RA initiation linked with lesser additional preventive medications.
-
6
Propensity score matching used for cohort balance.
-
7
Further trials are needed to confirm these findings.
Original Source(s)
GLP-1 RAs in Chronic Migraine
Investigators evaluate health care utilization and treatment patterns vs topiramate in an active-comparator study.
-
by Kathryn Wighton
March 3, 2026
-
3 min
Related Content
Sleep Apnea’s Billion-Dollar Toll
New analysis links untreated OSA to major productivity losses in working-age adults in the US and UK
February 25, 2026
-
2 min
Pablo E. Ravenna, M.D., Joins Marcus Neuroscience Institute as a Neuro-ophthalmologist
Neuro-ophthalmologist Pablo E. Ravenna, M.D., has joined Marcus Neuroscience Institute, part of Baptist Health.
COVID Tied to Hidden Smell Deficits
COVID-19 may leave behind unrecognized olfactory deficits linked to cognitive complaints.
September 30, 2025
-
2 min
